Hong Kong-listed Insilico Medicine signs AI drug development deal with Eli Lilly
Insilico Medicine has signed a potential multibillion-dollar deal with Eli Lilly to license out an early-stage drug pipeline and provide its artificial intelligence platform services in research and development collaborations. Under the agreement announced on Monday, US-headquartered, Hong Kong-listed Insilico will receive an upfront payment of US$115 million. The deal could have a total value of around US$2.75 billion tied to development, regulatory and commercial milestones, plus tiered...المصدر: South China Morning Post | Source: South China Morning Post
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة South China Morning Post. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by South China Morning Post. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
